In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best booming stocks to invest in now. The U.S. stock market closed on a downbeat ...

("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on January 27 and set a price target of $73.00. The company’s shares closed yesterday at ...

We can expect a number of other trial results from both AKRO and their competitors in the coming months. The disease formerly known as NASH (non-alcoholic steatohepatitis) was recently renamed in ...

The last time I wrote about Akero Therapeutics (NASDAQ:AKRO) it was with respect to a Seeking Alpha article entitled as "Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program".

In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note ...